Education Information



This activity is supported by independent educational grants from:

  • Aimmune Therapeutics
  • AstraZeneca
  • DBV Technologies
  • GlaxoSmithKline
  • Pharming Group NV
  • Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
  • Shire

This activity is also supported by Boehringer Ingelheim Pharmaceuticals, Dormer Laboratories Inc., Laerdal Medical, Micro Direct, Inc., Optim LLC and SmartPractice through independent educational grants consisting of loaned durable equipment and disposable supplies.


Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/Immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Overall Educational Objectives

At the conclusion of this activity, participants should be able to:

  • Identify major advances in key areas of cutting edge research in immunologic mechanisms and allergic responses, including anaphylaxis and pathophysiology of the upper airways, lungs, eyes, skin and gastrointestinal tract.
  • Demonstrate knowledge of basic processes linking molecular and cellular biology and genetics with allergic pathophysiology and immunodeficiency.
  • Translate emerging clinical science principles to clinical practice in patients with allergic and immunologic diseases.
  • Evaluate and implement state-of-the-art diagnostic and therapeutic strategies for treating patients with allergic and immunologic diseases.
  • Explain the impact of environmental exposures and external influences on patients with allergic disorders.
  • Recognize emerging trends in the prevalence of allergic and immunologic disorders and discuss their impact on public health.
  • Evaluate the impact of new diagnostic and therapeutic strategies on health care costs and outcomes.
  • Discuss processes, tools and technologies for the efficient allergy and immunology practice.

Disclosures

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (College) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, and/ or evaluation relevant to a CME activity. Disclosed information is reviewed in advance in order to manage and resolve any potential conflicts of interest. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations.

Specific disclosure information for the 2018 Annual Meeting is available now.


Accreditation Statement

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 32.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This continuing medical education activity has been reviewed by the American Academy of Pediatrics (AAP) and is acceptable for maximum of 32.5 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the AAP.

Advanced Practice Health Care Providers 1-Day Course:

This education activity will be submitted to the American Association of Nurse Practitioners for approval of up to 6.0 contact hours of accredited education.

Allied Health Professionals 1.5-Day Course:

This education activity will be submitted to the American Association of Nurse Practitioners for approval of up to 7.5 contact hours of accredited education.

Back to Top